Evaluation of the Necessary Amount of Financing of Drug Therapy for Particular Diseases

Willingness to pay analysis is an effective tool for decision-making. Purpose: to assess the necessary and justified level of funding for some nosologies from the position of specialists in economics and health. Materials and methods: cross-section interview survey to determine the maximum willingness to pay level. Results: Respondents have unanimously rated oncological diseases as one of the priority areas of funding. Opinions concerning financing orphan and most socially significant diseases markedly differ. Representatives of pharmaceutical companies noted the highest values reaching 10 million RUB a year, whilst in all cases the Federal Fund for Compulsory Medical Insurance specialists registered amounts not exceeding 100,000 RUB a year. Conclusions: the results of the research prove the necessity of creating a single communication platform for harmonizing the threshold of financing in healthcare system.